2017 Neurotech Leaders Forum

October 23-24, 2017

Embassy Suites, San Francisco Airport Waterfront

Tentative Agenda

Day One

8:00-8:30

Registration and Coffee

8:30-9:15

State of the Neurotechnology Industry: 2017

James Cavuoto, Editor and Publisher, Neurotech Reports
Neurotech Business Report Editor James Cavuoto provides his insights and observations on the state of the neurotechnology industry. He surveys changes in the competitive landscape that have occured over the years, the most significant events of the last year, and challenges confronting the industry in years ahead.
9:15-10:00

Keynote Address

Thomas Insel, M.D., President and Co-founder, Mindstrong Health
10:00-10:30

Refreshment Break, Sponsored by Heraeus Medical Components

10:30-11:15

Funding Tools for Neurotech Ventures

Jennifer French, Senior Editor, Neurotech Reports, Moderator
Stephanie Fertig, SBIR Project Manager, NIH/NINDS
Faz Bashi, M.D., Director, Angel Capital Association
Renee Ryan, Vice President, Johnson & Johnson Innovation
A wealth of new funding alternatives are now available for neurotech startups. In this session we'll look at traditional and nontraditional investment opportunites, including federal and state funding, crowdfunding, and incubators.
11:15-12:00

The Science of the Deal: Neurotech M&A Done Right

James Cavuoto, Editor, Neurotech Reports, Moderator
Jeff Erb, Senior Director of Business Development, Medtronic Neuromodulation
Scott Drees, CEO, Nuvectra
Mark Lindon, Principal, Lindon Law Corp.
In this session, entrepreneurs and executives from both sides of the M&A equation will share their experiences and advice. What are the best ways for neurotech startups to approach strategics? What are the best practices for assimilating an acquired firm into an existing operation?
12:00-1:30

Luncheon, Sponsored by Cirtec Medical

Neurotech Reports Staff Introductions
1:30-3:00

Neurotechnology Entrepreneur Panel

James Cavuoto, Editor, Neurotech Reports, Moderator
Tina Chang, Director of International Affairs, GIMER Medical
Bret Schneider, M.D., CMO, Zap Surgical
Ben Speck, Vice-President, Product Development, Stimwave LLC
This session features presentations from CEOs and executives of several neurotechnology start-up firms and more established technology ventures. Each executive will present an overview of their firm's technology and markets.
3:00-3:30

Refreshment Break

3:30-4:15

Supplier-Side Economics: Integrating Vendors into Commercialization

Jeremy Koff, Contributing Editor, Neurotech Reports, Moderator
Sean Harz, Director of Business Development, Cirtec Medical
Tom Hughes, Sr. Principal Advisor, Regulatory & Clinical Research Institute, Inc.
Randy Armstrong, CTO, Velentium
In this session, we'll look at the role that suppliers can play in the neurotech device commercialization process. Panelists will offer their advice on balancing the need for innovative device design with efficient and timely development and approval.
4:15-5:00

Frontiers in Brain Stimulation

James Cavuoto, Editor, Neurotech Reports, Moderator
Doug Weber, Ph.D., Associate Professor of Bioengineering, University of Pittsburgh, Director of Neuro R&D, Battelle
Ian Cook, M.D., Chief Translational Innovation Officer, UCLA Semel Institute for Neuroscience
Melanie McWade, Ph.D., Vice President of Emerging Therapies, Nexeon Medsystems
In this session, we'll look at advances in both implanted and noninvasive brain stimulation technologies and explore new applications on the horizon. We'll explore alternative DBS stimulation paradigms and report on progress in understanding the mechanisms of action of new therapies.
5:00-7:00

Cocktail Reception, Sponsored by MST

 
 

 

Day Two

8:00:8:30

Registration and Coffee

8:30-8:45

The Changing Face of Neuromodulation

James Cavuoto, Editor and Publisher, Neurotech Reports
Neurotech Reports editor James Cavuoto provides his insight on the new competitive landscape within the neuromodulation industry. New players and new technologies have emerged to alter market share in spinal cord stimulation, deep-brain stimulation, urinary incontinence, and other market segments.
8:45-9:15

Keynote Address

John Parker, Ph.D., CEO, Saluda Medical
9:15-10:00

Exoskeletons in Our Closet: The Challenge of Treating Paralysis

Jennifer French, Senior Editor, Neurotech Reports, Moderator
Andrew Cornwell, Ph.D., Director, Strategic and Industrial Collaborations, Cleveland FES Center
Chad Bouton, Vice-President, Advanced Engineering and Technology, Feinstein Institute for Medical Research
Nick Terrafranca, CEO, Neurorecovery Technologies
In this session, we'll examine three key technologies for restoring function to people with paralysis: robotic exoskeletons, FES, and epidural stimulation. We'll look at both the promise and the pitfalls of each as we chart the limits of what's possible in neuroprosthetics.
10:00-10:30

Coffee Break

10:30-11:15

Direct-to-Consumer: What Lies Ahead for Neurotech Therapies

James Cavuoto, Editor, Neurotech Reports, Moderator
Henry Mahncke, Ph.D., CEO, Posit Science Corp.
Shai Gozani, M.D., Ph.D., CEO, NeuroMetrix Inc.
Kelly Roman, Cofounder, Fisher Wallace Laboratories
In this session, we'll consider the pros and cons of marketing neurotech devices over the counter or without the need for regulatory approval. We'll explore the boundaries of neurotech "wellness" devices and consumer neurotech products.
11:15-12:00

Opportunities in Bioelectronic Medicine

Margot Puerta, Editor, Bioelectronic Medicine, Moderator
Kip Ludwig, Ph.D., Associate Director, Mayo Neural Engineering Laboratories
Daniel Chew, Ph.D., Director, Neuromodulation Group, Galvani Bioelectronics
Imran Eba, Partner, Action Potential Venture Capital
In this session, we'll hear from experts in the emerging field of bioelectronic medicine. We'll look at some of the new indications and new targets and we'll discuss partnering opportunities with bio/pharma firms.
12:00-1:30

Luncheon, Sponsored by Cirtec Medical

Presentation of 2017 Gold Electrode Awards
1:30-3:00

Neurotechnology Entrepreneur Panel

James Cavuoto, Editor, Neurotech Reports, Moderator
Daniel Rizzuto, Ph.D., CEO, Nia Therapeutics
Daniel McDonnall, Ph.D., President, Ripple LLC
Mark Peshoff, CEO, The FEMR Group
This session features presentations from CEOs and executives of several neurotechnology start-up firms and more established technology ventures. Each executive will present an overview of their firm's technology and markets.
3:00-3:30

Refreshment Break

3:30-4:15

The Market for Neurodiagnostics

Jennifer French, Senior Editor and Associate Publisher, Neurotech Reports, Moderator
Ann Bunnenberg, President, Electrical Geodesics (now Philips Neuro Diagnostics)
Jim Miller, CEO, Neuro Assessment Systems
Michael Szymanski, Ph.D., Director of Electrophysiology, Truust Neuroimaging
In this session, we'll cover advances in neurosensing and neurodiagnostic systems, including devices such as EEG headsets, brain-computer interfaces, and portable devices for assessing brain injury and dysfunction.
4:15-5:00

New Targets, New Interventions

Alison Fenney, Ph.D., Director, Industry Alliances, Neurotechnology Industry Organization, Moderator
Jeff Kramer, Ph.D., Vice President, Clinical Research, Kernel
Chris Czura, Ph.D., Vice President, Scientific Affairs, Feinstein Institute for Medical Research
In this closing session, we'll explore some promising new therapies on the horizon that challenge conventional thinking in neurostimulation devices. We'll look at combination therapies that combine stimulation with drug infusion, molecular medicine, and cell therapies.
5:00-7:00

Cocktail Reception, Sponsored by MST

 
 

 

site design by shalatdesign | shalat.com